There is one legal pathway to psilocybin therapy in Canada in 2026: Health Canada's Special Access Program (SAP), which a patient's prescribing physician or nurse practitioner uses to request psilocybin for an individual patient with a serious or life-threatening condition where conventional treatments have failed, are unsuitable, or are unavailable. Patients cannot apply directly. Section 56(1) class exemptions historically supported the first cohort of approvals (August 2020, four terminally ill Canadians via TheraPsil advocacy), and the January 5, 2022 SAP amendment created the durable practitioner-initiated pathway that operates today. The honest 2026 picture: this is a real and legal pathway that has authorized roughly 300 Canadian patients since 2022, and PsyCan reported a sharp decline in approvals through 2025 alongside lengthening review timelines. This article walks through the regulatory framework, who's typically eligible, the practical application steps, the Canadian drug supply, the 2025 access tightening, and how ATMA CENA supports SAP-pathway patients.

Key takeaways

The Health Canada Special Access Program (SAP) is the only legal pathway to psilocybin therapy in Canada. The January 5, 2022 amendment created the practitioner-initiated framework.

Patients cannot apply directly. A licensed physician or nurse practitioner submits a case-specific SAP request on behalf of an individual patient.

Documentation of failed conventional treatments at adequate dose and duration is required. Most approved cases are end-of-life distress or treatment-resistant depression with documented antidepressant failures.

Approval rates declined materially through 2025: PsyCan reported a sharp decline in approvals; cumulative SAP authorizations sit around 301 since the program opened (as of mid-2025). Review timelines have lengthened.

Drug supply is via Canadian licensed producers — Filament Health (often provides drug at no charge to SAP patients), Optimi Health, Psyence Group.

Quebec is the only province with a public-funding precedent (Farzin / Stephan billed RAMQ December 2022).

ATMA CENA supports preparation and integration for SAP-pathway patients via coordinated care. The medical SAP application is initiated by the patient's prescribing physician, not ATMA CENA directly.

Veterans Affairs Canada does NOT currently cover psilocybin (in contrast to ketamine).

The legal framework — three dates that matter

Pre-2022: Section 56(1) exemptions

Before the SAP amendment, psilocybin access required Section 56(1) exemptions under the CDSA — case-by-case, ministerial-approval-required, and rarely granted. Two milestones:

August 4, 2020: Health Canada granted Section 56(1) exemptions to four terminally ill Canadians for psilocybin-assisted therapy for end-of-life distress. The exemptions were the result of TheraPsil-led advocacy and represented the first legal therapeutic psilocybin access in Canada in decades.
December 2020: Health Canada granted Section 56 exemptions to 19 healthcare professionals for experiential training in psilocybin-assisted therapy.

These exemptions established proof-of-concept and built advocacy momentum but did not create a durable patient pathway.

January 5, 2022: SAP amendment — the durable pathway

Health Canada amended the Food and Drug Regulations to allow physicians and nurse practitioners to request psilocybin (and MDMA) through the Special Access Program for individual patients with serious or life-threatening conditions. The amendment removed restrictions that had previously excluded restricted drugs from SAP since 2013. Documents:

Health Canada notice: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy
Canada Gazette Part II publication of the amendment

This is the framework that operates today. The first SAP psilocybin authorization under the new framework was issued March 21, 2022 to Dr. Valorie Masuda (BC palliative) for six end-of-life patients.

December 2022: Quebec public funding precedent

Drs. Houman Farzin (Jewish General Hospital palliative psychiatry, McGill) and Jean-François Stephan successfully billed RAMQ for SAP-approved psilocybin-assisted therapy delivered to a Quebec patient with end-of-life distress. The June 2022 actual treatment was billed in December 2022; RAMQ subsequently modified billing codes to permit further public claims. Quebec remains the only province with established public funding for psilocybin-assisted therapy.

For the cost detail, see Psilocybin-Assisted Therapy Cost in Canada.

Who is typically eligible? Honest screening framing

Health Canada SAP authorizations are case-specific. The patterns from approved applications over 2022–2025:

Common SAP-approved indications

End-of-life distress / cancer-related psychiatric distress: the foundation indication; supported by Griffiths 2016, Ross 2016, Agin-Liebes 2020 long-term follow-up. See Psilocybin Therapy for End-of-Life Distress.
Treatment-resistant depression: documented failure of two or more antidepressant trials at adequate dose and duration; supported by Davis 2021 and Goodwin 2022.
Alcohol use disorder: less common; supported by Bogenschutz 2022.
Cluster headache: first SAP approval reported June 2024.
OCD, anorexia, demoralization in serious illness: case-by-case.

Common screening exclusions

Personal history of psychotic disorder (schizophrenia, schizoaffective, bipolar I)
First-degree family history of psychotic disorder (more conservative framing)
Active mania or recent hypomania
Uncontrolled cardiovascular disease, recent MI, severe structural heart disease
Pregnancy
Concurrent lithium (seizure case reports in published literature)
Active substance use disorder requiring stabilization
Inability to provide informed consent

Relative considerations

High-dose serotonergic antidepressants (SSRIs at high dose) — many trials taper before dosing under prescriber supervision; not always a hard exclusion
Severe personality disorder with marked instability
Complex trauma without adequate therapeutic alliance and prep capacity

The practical SAP application — how it works

The SAP application is physician- or NP-initiated — patients cannot apply directly. The 2026 process:

Step 1: Find a willing prescribing physician or nurse practitioner

This is the bottleneck. Most Canadian physicians have not applied for psilocybin SAP and many decline due to limited training, comfort with the regulatory process, and concern about clinical responsibility. Resources for finding willing prescribers:

TheraPsil maintains a directory of trained Canadian clinicians and offers free patient consultations to help match patients with prescribing physicians.
Numinus / Stella offers SAP-pathway support services.
Roots to Thrive in Nanaimo BC operates an SAP-authorized program with experience supporting end-of-life patients.
Quebec collective: Drs. Farzin and Stephan, and other Quebec palliative-psychiatry clinicians.
ATMA CENA's clinical team can discuss the SAP framework and where ATMA CENA's preparation/integration model fits, though ATMA CENA does not initiate SAP applications on patients' behalf.

Step 2: Document failed conventional treatments

The SAP request requires documentation of which conventional treatments have been tried, at what doses, for what duration, and why they failed, were unsuitable, or were unavailable. For TRD (treatment-resistant depression): typically two or more antidepressant trials at therapeutic dose for ≥6 weeks each in the current depressive episode. For end-of-life distress: documented psychiatric distress with palliative-care context. The prescribing physician compiles this documentation.

Step 3: Submit the SAP request

The prescribing physician completes the eight-page SAP request form, identifies a Canadian licensed psilocybin supplier, justifies the clinical rationale with reference to peer-reviewed evidence, and submits the request to Health Canada (typically by fax to 613-941-3194 or via the Health Canada SAP portal).

Step 4: Wait for case-specific authorization

Approval timelines historically ran 1–4 weeks; through 2025 timelines lengthened. PsyCan reported approval rates declining through 2025. Approval is case-specific — one patient, one application — and grants the prescribing physician authorization to obtain and administer the drug for that patient.

Step 5: Source the drug from a licensed supplier

Once authorized, the prescribing physician sources synthetic psilocybin from a Health Canada-licensed Canadian dealer:

Filament Health — first DEA-licensed Canadian natural psilocybin producer; PEX010 capsule; often provides drug at no charge to SAP-approved patients.
Optimi Health — synthetic psilocybin producer.
Psyence Group — natural psilocybin supplier.
Compass Pathways COMP360 — UK-based; Phase 3 active; limited Canadian SAP access.

Filament's no-charge SAP drug supply is a meaningful Canadian-specific cost reduction relative to international markets.

Step 6: Deliver the supervised clinical session

The psilocybin session is delivered in a supervised clinical setting under the prescribing physician's authorization, with the standard three-phase model: preparation, dosing (6–8 hours), integration. The prescribing physician retains medical responsibility throughout.

Step 7: Submit the post-treatment Form C report

After the treatment, the physician completes Health Canada's Form C reporting the outcome, adverse events (if any), and clinical observations. This data informs Health Canada's ongoing program oversight.

The 2025 access tightening — honest framing

The SAP pathway through 2025 changed materially. PsyCan (Psychedelics Canada, the Canadian psychedelic medicine trade association) published a September 2025 report on the sharp decline in Health Canada SAP approvals for psilocybin and MDMA. Reported figures:

2022 (post-amendment year): ~56 approvals
2023: ~106 approvals (peak year)
2024: ~104 approvals
2025 (through mid-year): ~35 approvals — significant decline

Cumulative approvals reached approximately 301 by mid-2025 since the January 2022 amendment. Approval timelines lengthened. The decline coincided with broader political shifts in 2025; PsyCan and TheraPsil have advocated for processing improvements.

The honest takeaway for patients researching SAP-pathway psilocybin therapy in 2026: the pathway is real but materially harder to access than in 2023–2024. Plan for:

Substantial time investment to find a willing prescriber.
Clear documentation of conventional treatment failures.
A 2–8 week (or longer) SAP review timeline.
Out-of-pocket therapy cost (CAD $2,500–$6,500; Quebec RAMQ exception for eligible patients).
The possibility that the application may not be approved.

TheraPsil — the foundational advocacy and training organization

TheraPsil is the Canadian non-profit founded in 2019 by Dr. Bruce Tobin (clinical psychologist) and Spencer Hawkswell. The organization secured the August 2020 Section 56(1) exemptions for the first four terminally ill Canadian patients and has remained at the centre of Canadian SAP-pathway work since.

Functions:

Patient SAP-application support: free consultations matching patients with trained prescribing physicians and therapists.
Clinician training: Canadian-context psilocybin-assisted therapy training programs.
Advocacy: regulatory engagement; ongoing constitutional challenge work.
Research: TheraPsil supports clinical research including the PsilWell wellness study.
Tobin v. Canada / Toth v. Canada: ongoing constitutional and federal court challenges to access barriers; refer to TheraPsil and recent reporting for current status.

For Canadian psilocybin therapy training context, see Psychedelic Therapy Training in Canada.

Where ATMA CENA fits in the SAP pathway

ATMA CENA's role in the SAP-pathway psilocybin landscape is specific and worth framing honestly:

ATMA CENA does not initiate SAP applications. The medical SAP request is initiated by the patient's prescribing physician or nurse practitioner.
ATMA CENA supports preparation and integration for patients pursuing the SAP pathway. The ATMA CENA three-phase psychedelic-assisted therapy model adapts to psilocybin where SAP authorization is in place.
The coordinated care model lets a patient's existing therapist remain the primary therapeutic relationship while ATMA CENA's clinical infrastructure provides the psychotherapy wraparound and clinical coordination specific to dosing.
ATMA CENA's training program prepares clinicians for psychedelic-assisted therapy work, including the foundations applicable to SAP-pathway psilocybin support. See the training cluster.

The ATMA CENA intake call is the practical entry point: a 15-minute clinical conversation about whether the SAP pathway fits, what documentation a patient would need to gather, what TheraPsil and other Canadian providers might be appropriate matches, and how ATMA CENA's preparation/integration model would work alongside.

Frequently asked questions

Can I apply for SAP myself as a patient? No. SAP applications are physician- or nurse-practitioner-initiated. You need a prescribing clinician willing to apply on your behalf.

How do I find a physician willing to apply? TheraPsil maintains a directory of trained Canadian clinicians and offers free consultations to help match patients with prescribing physicians. Numinus and Roots to Thrive also support SAP-pathway work. Quebec providers (Farzin, Stephan, others) have RAMQ public-funding precedent. ATMA CENA's intake call can discuss your situation and orient you to appropriate resources.

What's the approval rate? Historical approval rates were roughly ~78% per industry reporting through 2024. PsyCan reported a sharp decline through 2025; cumulative approvals reached ~301 by mid-2025 since January 2022.

How long does SAP review take? Historically 1–4 weeks; through 2025, timelines lengthened materially. Plan for 2–8 weeks or longer in 2026.

What documentation does my physician need? Diagnosis of a serious or life-threatening SAP-eligible condition; documentation of conventional treatment failures (e.g., two or more adequate antidepressant trials for TRD); justification with peer-reviewed evidence; identification of a Canadian licensed drug supplier; the eight-page SAP request form.

Where does the drug come from? A Health Canada-licensed Canadian producer: Filament Health (often at no charge for SAP patients), Optimi Health, or Psyence Group. Some Compass Pathways COMP360 has been imported.

Does VAC cover psilocybin therapy for veterans? No — VAC does not currently cover psilocybin-assisted therapy. This is a meaningful contrast to ketamine, which VAC covers for service-related TRD or chronic pain on a case-by-case basis.

Does private insurance cover psilocybin therapy? Generally no. The drug itself is not covered (Schedule III, no approved indication). Therapy fees (preparation/integration psychotherapy) may be partially covered as standard psychotherapy when delivered by a covered profession.

What's the Quebec RAMQ pathway? Drs. Houman Farzin (Jewish General Hospital palliative psychiatry) and Jean-François Stephan billed RAMQ for SAP-approved psilocybin-assisted therapy delivered to a patient with end-of-life distress in December 2022. RAMQ subsequently modified billing codes for further public claims. Quebec is the only province with this public-funding precedent.

Can a nurse practitioner apply for SAP? Yes. The January 2022 amendment authorized both physicians and nurse practitioners to submit SAP requests for psilocybin and MDMA.

What conditions has Health Canada approved? End-of-life distress (most common), treatment-resistant depression, alcohol use disorder, cluster headache, OCD, anorexia, demoralization — case-by-case.

Does ATMA CENA initiate the SAP application? No. ATMA CENA's role is supporting preparation and integration; the medical SAP application is initiated by the patient's prescribing physician or nurse practitioner.

What if my application is denied? Denial is possible — particularly under 2025's tightened approval rates. Options include resubmitting with additional documentation, identifying a different prescriber, or pursuing alternative treatments (e.g., ketamine therapy, ECT, or other CANMAT-recommended TRD pathways). ATMA CENA's clinical team can discuss alternatives.

Sources

ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html
Government of Canada — Psilocybin and psilocin: https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.html
TheraPsil: https://therapsil.ca/
TheraPsil — SAP psilocybin: https://therapsil.ca/sap-psilocybin/
PsyCan — Sharp decline in SAP approvals (September 2025): https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
Filament Health: https://filament.health/
Optimi Health: https://www.optimihealth.ca/
Psyence Group: https://psyence.com/
TheraPsil — Quebec first province to cover psilocybin therapy: https://therapsil.ca/quebec-first-province-to-cover-costs-of-psilocybin-assisted-psychotherapy-done-by-two-physicians/

How to Access Psilocybin Therapy in Canada

Psilocybin access is restricted in many places